(Q38542411)

English

A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome

scientific article published on 03 July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

1 reference

Europe PubMed Central

A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

1 reference

based on heuristic

inferred from title

Falk Nimmerjahn

1

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

language of work or name

0 references

publication date

3 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

European Journal of Immunology

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

2183-2190

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Patterns of transmitted HIV drug resistance in Europe vary by risk group

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Antibodies in HIV-1 vaccine development and therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

A requirement for FcγR in antibody-mediated bacterial toxin neutralization

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Fc receptor-mediated antiviral antibodies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Fcgamma receptors as regulators of immune responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Impact of immune complex size and glycosylation on IgG binding to human FcγRs

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Of mice and men: the need for humanized mouse models to study human IgG activity in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Fcgamma receptors: old friends and new family members

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Cytotoxic antibodies trigger inflammation through Fc receptors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Fc receptors are required in passive and active immunity to melanoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

FcR gamma chain deletion results in pleiotrophic effector cell defects

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Sensitizing protective tumor microenvironments to antibody-mediated therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

How immunoglobulin G antibodies kill target cells: revisiting an old paradigm

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Broadly neutralizing antiviral antibodies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

HIV: Roadmaps to a vaccine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Fc receptor but not complement binding is important in antibody protection against HIV.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

FcRn: the neonatal Fc receptor comes of age.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

Low level of FcγRIII expression on murine natural killer cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

A Humanized Mouse Identifies the Bone Marrow as a Niche with Low Therapeutic IgG Activity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

21 January 2018

New CDC guidelines recommend circumcision to cut HIV risk

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

7 January 2021

based on heuristic

inferred from DOI database lookup

Roles of Fc receptors in autoimmunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201445386

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/EJI.201445386

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38542411&oldid=2097606729"